These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11166143)

  • 1. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer.
    Antman KH
    Eur J Cancer; 2001 Jan; 37(2):173-9. PubMed ID: 11166143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trials of high-dose chemotherapy in breast cancer: fraud, the press and the data (or lessons learned in medical policy governing clinical research).
    Antman K
    Trans Am Clin Climatol Assoc; 2002; 113():56-66; discussion 66-7. PubMed ID: 12053718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose adjuvant chemotherapy for breast cancer: state of the art.
    Cottu PH; Cuvier C; Espié M
    Forum (Genova); 2002; 12(1):36-40. PubMed ID: 12634909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.
    Cameron D; Morden JP; Canney P; Velikova G; Coleman R; Bartlett J; Agrawal R; Banerji J; Bertelli G; Bloomfield D; Brunt AM; Earl H; Ellis P; Gaunt C; Gillman A; Hearfield N; Laing R; Murray N; Couper N; Stein RC; Verrill M; Wardley A; Barrett-Lee P; Bliss JM;
    Lancet Oncol; 2017 Jul; 18(7):929-945. PubMed ID: 28600210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
    Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whither high-dose chemotherapy in breast cancer?
    Mayer A; Earl H
    Breast Cancer Res; 2001; 3(1):8-10. PubMed ID: 11250740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.
    Cole BF; Gelber RD; Gelber S; Coates AS; Goldhirsch A
    Lancet; 2001 Jul; 358(9278):277-86. PubMed ID: 11498214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose chemotherapy in breast cancer.
    Lake DE; Hudis CA
    Drugs; 2004; 64(17):1851-60. PubMed ID: 15329034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data.
    Tartarone A; Romano G; Galasso R; Iodice G; D'Arena G; Coccaro M; Bochicchio A; Sgambato A; Di Renzo N
    Bone Marrow Transplant; 2003 Apr; 31(7):525-30. PubMed ID: 12692616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
    Matikas A; Margolin S; Hellström M; Johansson H; Bengtsson NO; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
    Breast Cancer Res Treat; 2018 Apr; 168(2):349-355. PubMed ID: 29190004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trials of high dose chemotherapy for breast cancer.
    Antman KH
    Biochim Biophys Acta; 2001 Mar; 1471(3):M89-98. PubMed ID: 11250065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
    Farquhar C; Basser R; Marjoribanks J; Lethaby A
    Cochrane Database Syst Rev; 2003; (1):CD003139. PubMed ID: 12535457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [High-dose chemotherapy in breast cancer].
    Schmid P; Possinger K
    Med Klin (Munich); 2002 Nov; 97(11):677-86. PubMed ID: 12434276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.